Lifevantage Corp.
- LFVN · Nasdaq
- Pharmaceutical Preparations
- Lehi, UT
- 223 employees
- CIK 0000849146
Updated from SEC filings through
Top things to know
Executives
- Terrence Moorehead President and CEO 4, 2026-08-10
-
Carl Aure Chief Financial Officer 4, 2026-09-14 -
Kristen Cunningham Chief Sales Officer 4, 2026-09-14 - Todd Thompson Chief Information Officer 4, 2025-12-29
- Alissa Neufeld General Counsel 4, 2026-07-06
-
Michael Beindorff Interim President and Chief Executive Officer DEF 14A, 2026-09-18
What leadership is saying
“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it”
Earnings press release (8-K Ex. 99.1), filed November 9, 2026
Lifevantage Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Lehi, UT. It trades as LFVN on Nasdaq. Revenue was $183M in the fiscal year ending June 30, 2026, -20.1% from the year before. It reported about 223 employees. Terrence Moorehead is President and CEO.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $183M 10-K, 2026-08-27 | $229M 10-K, 2026-08-27 | $200M 10-K, 2025-09-04 | $213M 10-K, 2024-08-28 | $206M 10-K, 2023-08-28 |
| Operating income | $6.1M 10-K, 2026-08-27 | $12.2M 10-K, 2026-08-27 | $4.3M 10-K, 2025-09-04 | $4.3M 10-K, 2024-08-28 | $7.6M 10-K, 2023-08-28 |
| SG&A | $58.4M 10-K, 2026-08-27 | $69.2M 10-K, 2026-08-27 | $68.5M 10-K, 2025-09-04 | $71.1M 10-K, 2024-08-28 | $63.4M 10-K, 2023-08-28 |
| Net income | $5.1M 10-K, 2026-08-27 | $9.8M 10-K, 2026-08-27 | $2.9M 10-K, 2025-09-04 | $2.5M 10-K, 2024-08-28 | $3.1M 10-K, 2023-08-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Michael Beindorff | Named in proxy bio: Interim President and Chief Executive Officer | DEF 14A, 2026-09-18 |
| Terrence Moorehead | President and CEO | 4, 2026-08-10 |
| Carl Aure Chief Financial Officer at LifeVantage Corporation | Chief Financial Officer | 4, 2026-09-14 |
| Kristen Cunningham Sales Executive | Chief Sales Officer | 4, 2026-09-14 |
| Todd Thompson | Chief Information Officer | 4, 2025-12-29 |
 Michelle Oborn | Named in proxy bio: Chief People Officer | DEF 14A, 2025-09-19 |
| Julie Boyster | Named in proxy bio: Chief Marketing Officer | DEF 14A, 2025-09-19 |
| Alissa Neufeld General Counsel at 1-800 CONTACTS | General Counsel | 4, 2026-07-06 |
| Dayton Judd | Board member (per proxy) bio: Director | DEF 14A, 2026-09-18 |
 Raymond B. Greer | Board member (per proxy) bio: Chairman, Independent Director | DEF 14A, 2025-09-19 |
| Cynthia Latham | Board member (per proxy) bio: Independent Director | DEF 14A, 2025-09-19 |
| Darwin K. Lewis | Board member (per proxy) bio: Independent Director | DEF 14A, 2025-09-19 |
| Michael A. Beindorff | Board member (per proxy) bio: Independent Director | DEF 14A, 2025-09-19 |
| Rajendran Anbalagan | Board member (per proxy) bio: Independent Director | DEF 14A, 2025-09-19 |
What Lifevantage Corp does
LifeVantage Corporation (the “Company,” “LifeVantage,” “we,” “us,” or “our”) is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants.
Shares and governance
| Shares outstanding | 12.7 million (as of November 6, 2026) | 10-Q, November 9, 2026 |
|---|---|---|
| Public float | $63.7M (as of December 31, 2025) | 10-K, August 27, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting November 5, 2026 (filed September 18, 2026) | DEF 14A, September 18, 2026 |
| Auditor | Deloitte & Touche LLP (Salt Lake City, Utah) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 15, 2026 | Darwin Lewis Director | Buy | 976 | $6K | Form 4, September 17, 2026 |
| September 14, 2026 | Kristen Cunningham Chief Sales Officer | Sale | 9,001 | $56K | Form 4, September 14, 2026 |
| June 15, 2026 | Darwin Lewis Director | Buy | 705 | $6K | Form 4, June 17, 2026 |
| June 3, 2026 | Michael A. Beindorff Director | Sale | 10,000 | $86K | Form 4, June 5, 2026 |
| March 16, 2026 | Darwin Lewis Director | Buy | 1,055 | $6K | Form 4, March 18, 2026 |
| March 2, 2026 | Judd Dayton Director | Buy | 33,197 | $152K | Form 4, March 2, 2026 |
| February 9, 2026 | Darwin Lewis Director | Buy | 3,955 | $21K | Form 4, February 11, 2026 |
| December 15, 2025 | Darwin Lewis Director | Buy | 805 | $5K | Form 4, December 17, 2025 |
Recent 8-K events
- 8-K filed 2026-10-05
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2026-08-27
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-16
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-12-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-11-12
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2025-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-04
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Lifevantage Corp
- What does Lifevantage Corp do?
- In its own words, from Item 1 of its 10-K: "LifeVantage Corporation (the “Company,” “LifeVantage,” “we,” “us,” or “our”) is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants."
- What is Lifevantage Corp's revenue?
- $183M for the fiscal year ending June 30, 2026, from its 10-K filed August 27, 2026.
- Is Lifevantage Corp profitable?
- Lifevantage Corp reported net income of $5.1M for the fiscal year ending June 30, 2026.
- How many employees does Lifevantage Corp have?
- About 223 as of June 30, 2026, as stated in its annual report.
- Who is the CEO of Lifevantage Corp?
- Terrence Moorehead, President and CEO, as named in a 4 filed August 10, 2026.
- Who is the CFO of Lifevantage Corp?
- Carl Aure, Chief Financial Officer, as named in a 4 filed September 14, 2026.
- Where is Lifevantage Corp headquartered?
- Lehi, UT.
- What is Lifevantage Corp's stock ticker?
- LFVN on Nasdaq.
- What industry is Lifevantage Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Lifevantage Corp's website?
- lifevantage.com.
- When does Lifevantage Corp report earnings next?
- November 9, 2026. Source: pg_earnings_events.
- Is Lifevantage Corp a public company?
- Yes. Lifevantage Corp files with the SEC under CIK 0000849146 and trades as LFVN.
- Who audits Lifevantage Corp?
- Deloitte & Touche LLP, Salt Lake City, Utah, as named in its latest annual report (10-K).
- How many shares of Lifevantage Corp are outstanding?
- 12.7 million shares as of November 6, 2026, from its 10-Q filed November 9, 2026.
- What is Lifevantage Corp's public float?
- $63.7M as of December 31, 2025, as reported on the cover of its 10-K filed August 27, 2026.
- How many business segments does Lifevantage Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is Lifevantage Corp's annual shareholder meeting?
- November 5, 2026, per its proxy statement (DEF 14A) filed September 18, 2026.
- Have Lifevantage Corp insiders traded stock recently?
- Since July 1, 2025, officers and directors reported 6 open-market sales worth about $558K and 7 purchases worth about $201K on Forms 4 and 5. The most recent: Darwin Lewis (Director) bought 976 shares on September 15, 2026.